Navigation Links
Metabolic Solutions Development Company To Test Potential Treatment for Alzheimer's
Date:10/12/2009

KALAMAZOO, Mich., Oct. 12 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

ADDF funding will support a collaboration between Dr. Douglas Feinstein (Jesse Brown VA Medical Center and University of Illinois at Chicago) and MSDC. Feinstein's research focuses on neurodegenerative diseases while MSDC is developing novel treatments for type 2 diabetes and related metabolic diseases.

"Initial findings in our ongoing research suggest that some insulin sensitizers, including MSDC's lead compound MSDC-0160, currently in Phase II studies for the treatment of type 2 diabetes, might slow down the buildup of plaques in the brains of mice," said Feinstein. "These mice are engineered to develop plaques similar to those found in the brains of patients with Alzheimer's. Positive results from these studies would encourage further investigation of MSDC-0160 in the treatment of Alzheimer's."

Initial findings were presented at the 10th Annual International Conference on Alzheimer's Drug Discovery (www.alzdiscovery.org) in Jersey City, N.J. and demonstrated that a one-month treatment of MSDC-0160 can reduce both the number and size of the amyloid plaques in mice. Ongoing studies are evaluating whether the compound can improve the cognitive deficits in the Alzheimer's mouse model.

"We are very enthusiastic about the potential of MSDC's compound for Alzheimer's disease," said Howard Fillit, MD, ADDF's executive director. "Our relationship is another demonstration that venture philanthropy funds can provide a critical catalyst for innovative drug discovery research conducted by biotechnology companies such as MSDC."

Earlier this year, MSDC reported that a Phase IIa clinical trial in type 2 diabetic patients showed that MSDC-0160 can improve insulin response and lower glucose in individuals with type 2 diabetes without producing the weight gain seen with currently marketed PPAR-activating insulin sensitizers. MSDC-0160 and MSDC's other insulin sensitizers work through a novel target discovered by the company's founders while minimizing PPAR activation.

Numerous scientific studies have shown a link between type 2 diabetes, cognitive impairment and Alzheimer's disease. Some studies have implied that measures to prevent or control diabetes may lower the risk of dementia and suggested that certain diabetes drugs should be tested to find out whether they can help Alzheimer's patients.

"This funding from the ADDF is an important first step in what could be a key development in the treatment of Alzheimer's," said Jerry Colca, president and chief scientific officer of MSDC. "For MSDC, if our compounds can reverse cognitive impairments in animal models, this may have important implications for the treatment of type 2 diabetes as well."

About Metabolic Solutions Development Company:

Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.

The company's scientific strategy is built on a historical understanding of insulin-sensitizers and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.

About Alzheimer's Drug Discovery Foundation (ADDF):

ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 2,000 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than $36 million to fund more than 270 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries. The ADDF website explores headline news on Alzheimer's disease, updated weekly.

    CONTACT:
    Nick Wasmiller
    Seyferth & Associates Inc.
    1-800-435-9539
    wasmiller@seyferthpr.com

SOURCE Metabolic Solutions Development Company


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
4. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
5. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
6. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
7. NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease
8. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Ethicon Endo-Surgery Introduces Innovation-Enabling Solutions Across the Spectrum of Surgery at ACS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... VIENNA and TAIPEI, Taiwan , ... 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea ... demonstrated a significantly better safety and tolerability profile of ropeginterferon ... data from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV ... PharmaEssentia intends to present this data to the ...
(Date:12/4/2016)... ORLEANS , Dec. 2, 2016  Former Attorney General ... Jr., Esq. , a partner at the law firm of ... commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in Generic-Drug ... "antitrust investigation by the Justice Department, begun about two years ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):